Mirum Pharmaceuticals, Inc. Proceeds from Issuance of Private Placement
Mirum Pharmaceuticals, Inc. (MIRM) reported Proceeds from Issuance of Private Placement of $259.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2026-06-30 was $0.00.
- Mirum Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2026-03-31 was $259.95M.
- Mirum Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2025-06-30 was $0.00.
- Mirum Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2025-03-31 was $0.00.
- Mirum Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2025 was $0.00.
- Mirum Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Mirum Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2023 was $202.20M.
- Mirum Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Private Placement | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $259.95M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $259.95M 10-Q · filed 2026-05-06 | ||||
| 2026-01-23 | $259.90M 10-Q · filed 2026-08-05 | ||||
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | ||||
| 2023-12-31 | -$159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $202.20M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $202.36M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $0.00 10-K · filed 2024-03-15 | ||||
| 2020-12-31 | $10.00M 10-K · filed 2022-03-09 | ||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |